Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	21
Overall Study	STARTED	Omalizumab 75 mg	23
Overall Study	STARTED	Omalizumab 300 mg	25
Overall Study	STARTED	Omalizumab 600 mg	21
Overall Study	COMPLETED	Placebo	15
Overall Study	COMPLETED	Omalizumab 75 mg	17
Overall Study	COMPLETED	Omalizumab 300 mg	23
Overall Study	COMPLETED	Omalizumab 600 mg	16
Overall Study	NOT COMPLETED	Placebo	6
Overall Study	NOT COMPLETED	Omalizumab 75 mg	6
Overall Study	NOT COMPLETED	Omalizumab 300 mg	2
Overall Study	NOT COMPLETED	Omalizumab 600 mg	5

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00866788/flow